Skip over navigation
Banner
Industry
Directory Facilities Technology Transfer Economic Develop. CO BioHistory (TM)
Career
Job Search Post a Job Submit Resume Destination CO
News/Events
Local CO News Submit News Release Calendar Submit Event CEO Reading
Patient
Clinical Trials Local Support National Resources
Education
K-12 Higher Ed BioEd Reading
About
Advertising Feedback Home
 
About
 Advertising
 Feedback
 Home
Quick Links
 Directory
 Job Search
 Facilities
 Calendar
 Advertising
Community Service Ad: Athena Partners - Eliminating women's cancers
Jobs
 
Events
 

NEW University of Washington Basic Bioscience Certificate starts Jan 2009

UW M.S. in Biomedical Regulatory Affairs with evening classes for working professionals


Medchem Source

Local News

Submit News Release


Search Articles: 

  • FDA issues a Complete Response Letter for Lilly's olanzapine LAI  Eli Lilly and Company announced that it received a complete response letter from the U.S. Food and Drug Administration (FDA) for olanzapine long-acting injection (LAI) for acute and maintenance treatment of schizophrenia in adults.
    Eli Lilly and Company January 07, 2009  
  • Health care could nab $100B payday  The $775 billion economic stimulus plan being cobbled together by President-elect Barack Obama and congressional Democrats could pump more than $100 billion into the health care sector, modernizing its delivery system and providing care to those who lost their health insurance.
    Politico January 07, 2009  Chris Frates
  • Monsanto takes major step toward launch of world's first drought-tolerant corn product  As farmers around the world search for innovative new technologies to help them produce more with fewer resources, Monsanto Company announced that it is a major step closer to delivering the world's first-ever drought-tolerant corn product to farmers.
    Monsanto Company January 07, 2009  
  • Monsanto increases full-year ongoing EPS guidance after reporting 117% earnings for 1Q2009  Greater demand in Latin America for Monsanto Company's products propelled the company to record-setting net sales and net income results for its fiscal 2009 first quarter, which ended Nov. 30, 2008.
    Monsanto Company January 07, 2009  
  • BiOptix: Small steps to big dreams with biomolecule detection system  The excitement is evident in Founder and CEO Dr. Misha Plam's eyes when he talks about the 2009 launch of the BiOptix biomolecule detection system. It creates possibilities in many markets – from fast and accurate point of care diagnostics to biological warfare agent detection and forensics.
    RockyRadar January 06, 2009  
  • Kansas is the right choice for NBAF  The selection of Kansas and Kansas State University as the "preferred site" for the National Bio and Agro-Defense Facility (NBAF) is profoundly meaningful for our state and good news for the nation.
    Governor of Kansas January 06, 2009  
  • U.S. Patent Office accepts Pfizer’s reissue application on Lipitor enantiome patent  Pfizer announced that the U.S. Patent & Trademark Office has issued a "Notice of Allowance" accepting the company's application to correct the technical defect in the '995 enantiomer patent for atorvastatin calcium, the salt form of atorvastatin sold as Lipitor.
    Pfizer Inc. January 06, 2009  
  • Johnson & Johnson extends tender offer for Mentor Corporation  Johnson & Johnson announced it has extended its previously announced cash tender offer, through its wholly owned subsidiary, Maple Merger Sub, for all outstanding shares of common stock of Mentor Corporation until 5:00 p.m. (Eastern time), on January 16, 2009, unless further extended.
    Johnson & Johnson January 06, 2009  
  • Monsanto announces yield gains with Deltapine Class Of 09  Monsanto Company announced its D&PL business will market five new varieties as the Deltapine Class of 09 for the coming production season. These varieties were introduced during the 2009 Beltwide Cotton Conferences that have brought the cotton industry together in San Antonio.
    Monsanto Company January 06, 2009  
  • Abbott completes acquisition of Ibis Biosciences, a subsidiary of Isis  Isis Pharmaceuticals and Abbott announced that Abbott has completed its purchase of Ibis Biosciences, an Isis subsidiary, for a closing purchase price of $175 million.
    Isis Pharmaceuticals, Inc. January 06, 2009  

   (next 10 articles)

Search Articles: 


Submit News Release

 
Email thie page to a friend. Email This Page
to a Friend
Print this page. Print This
Page

© 2009 Info.Resource, Inc. All rights reserved.
Privacy Policy . Terms of Use . Advisory Board . Advertising

ColoradoLifeScience.com, owned and published by Info.Resource, Inc., is a resource
for the life science industry in the state of Colorado.